Key Takeaways Esperion named ESP-2001 its new preclinical candidate for primary sclerosing cholangitis.ESP-2001 was discovered with Evotec and has shown liver injury reduction in preclinical studies.Esperion will hold exclusive global rights to develop and commercialize ESP-2001.Esperion Therapeutics (ESPR) announced that it has nominated ESP-2001, a highly specific allosteric ATP citrate lyase (“ACLY”) inhibitor, as its new preclinical development candidate for the treatment of primary sclerosing cholangit ...